Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836–1892)

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Kampen KR. The discovery and early understanding of leukemia. Leuk Res. 2012;36:6–13.

    Article  Google Scholar 

  2. Piller GJ. Leukaemia—a brief historical review from ancient times to 1950. Br J Haematol. 2001;112:282–92.

    CAS  Article  Google Scholar 

  3. Mehranfar S, Zeinali S, Hosseini R, Mohammadian M, Akbarzadeh A, Feizi AHP. History of leukemia: diagnosis and treatment from beginning to now. Galen Med J. 2017;6:12–22.

    Article  Google Scholar 

  4. Lissauer D. Zwei Fälle von Leucaemie. Berl klin Wochenschr. 1865;2:403–4.

    Google Scholar 

  5. Cullen WR. Medicinal arsenic: toxic arsenic. In: Kapper P, Cullen WR (eds). Is arsenic an aphrodisiac?: The sociochemistry of an element. Cambridge, UK: Royal Society of Chemistry; 2008. p. 1–55.

  6. Manley PW, Stiefl NJ. Progress in the discovery of BCR-ABL kinase inhibitors for the treatment of Leukemia. Top Med Chem. 2018;28:1–37.

    CAS  Google Scholar 

  7. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.

    Article  Google Scholar 

  8. Kumana CR, Mak R, Kwong Y-L, Gill H. Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: a historical account from bedside to bench to bedside. Front Oncol. 2020;10:1294.

    Article  Google Scholar 

  9. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11:123.

    Article  Google Scholar 

  10. Brosius CM. Die Asyle Bendorf und Sayn bei Coblenz und die damit verbundene Colonie für Gehirn, und Nervenkranke nebst Bemerkungen über Curmittel bei Irren. August Hirschwald, Berlin 1867. Reprinted by AbeBooks. 2021.

  11. Lissauer. Das Asyl für Gehirn- und Nervenkranke zu Bendorf bei Coblenz unter Direction des Dr. C. Brosius: Siebenter Jahresberichte pro 1863. Preussische Medicinal Ztg Neue Folge VII Jahrg. 1864;13:101–2.

    Google Scholar 

  12. Königlich Preußischer Staatsdienst-Kalender für den Regierungsbezirk Cassel. 1873. p. 111.

  13. “Lissauer, David Dr. med. (1892); Lissauer, Friederike geborene Michaelis (1911)—Fritzlar”, in: Jüdische Grabstätten:

Download references

Author information

Authors and Affiliations



PWM researched and authored this article.

Corresponding author

Correspondence to Paul W. Manley.

Ethics declarations

Competing interests

PWM is an employee of Novartis Pharma AG, Basel, Switzerland.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Manley, P.W. Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836–1892). Leukemia 36, 1697–1698 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links